Bayer Stock Holds Above Key Moving Average as Court Dates and a Biotech Takeover Loom
Published on 06/20/2026 at 17:41 | Redaktion boerse-global.de
The shares of Bayer have crept back above a technical threshold that traders are watching closely. At the close on Friday, the stock settled at €37.81, narrowly clearing the 50-day moving average, after a 4.85% gain over the week. Yet the real test for the German pharmaceutical and agriculture group is not chart-driven — it comes from a pair of landmark US court hearings and a newly closed deal in eye-care.
A $300M Bet on Eye Disease
Bayer confirmed it has wrapped up the acquisition of Perfuse Therapeutics, a private biotech focused on retinal diseases. The upfront payment is roughly $300 million, but the total deal value can climb to $2.45 billion if all development and sales milestones are met. The centrepiece is PER-001, an intravitreal implant designed to treat glaucoma and diabetic retinopathy. The drug candidate is currently in Phase II trials and was built on Perfuse’s proprietary sustained-release platform. Bayer is folding it into its ophthalmology portfolio, a move that CEO Bill Anderson sees as strengthening the pharma pipeline.
But that pipeline also faces headwinds. Bayer’s prostate-cancer drug Nubeqa is locked in a legal fight with Johnson & Johnson. In February, Bayer sued J&J, alleging that J&J’s rival drug Erleada is being marketed with a flawed real-world analysis that wrongly claims superiority. A federal judge in Manhattan refused to block those statements — a setback for Bayer. Then, on June 15, Bayer filed an amended complaint seeking a permanent injunction and damages. The stakes are high: Nubeqa booked €1.92 billion in sales over the first nine months of 2025, while Erleada generated €2.62 billion.
Supreme Court and a Settlement Hearing Dominate the Calendar
The bigger legal overhang for Bayer remains glyphosate. The US Supreme Court is set to weigh a fundamental question: whether federal warning labels on Roundup should pre-empt state-level duties to warn. The outcome will shape the direction of future lawsuits. Separately, a US judge has sent a proposed multibillion-dollar settlement back to a court in Missouri. The original settlement was valued at $7.25 billion. A critical hearing is scheduled for July 9.
Should investors sell immediately? Or is it worth buying Bayer?
With both events imminent, the stock is primed for volatility. A favourable Supreme Court ruling could reinforce the recent breakout above the 50-day line. Should the shares slip back below €37.80, a rapid pullback is on the cards.
Cash Flow Pressures and Analyst Divergence
The legal efforts come at a cost. For 2026 alone, Bayer expects roughly €5 billion in cash outflows tied to ongoing litigation. Free cash flow could turn as negative as €2.5 billion, and net financial debt may swell to €33 billion by year-end. Management is counting on stronger revenue from the agricultural and consumer health segments to help offset the drain.
Against that backdrop, analysts are split. UBS has a price target of €52, with analyst Matthew Weston highlighting the potential in both the pharma and crop-science divisions. Jefferies is more cautious, setting a target of €40.
Bayer at a turning point? This analysis reveals what investors need to know now.
Technically, the stock has risen more than 50% from its 52-week low of €25.09, but remains about 24% below its 52-week high of €49.93. The weekly advance of 4.85% has pushed it above the 200-day moving average as of June 17, but the real catalysts — and the real risks — lie in the courtroom.
Ad
Bayer Stock: New Analysis - 20 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
